BRIEF—New Taiwan policy allows certain treatments without clinical trials

Six autologous cell therapies now can be used to treat certain indications in Taiwan without going through clinical trials, according to a newly amended policy issued by Taiwan's Ministry of Health and Welfare to push the biotech development in the island.

While four of the ACTs are used in surgeries, two of them - immunotherapy and CD34+selection peripheral blood cell transplantation - are for cancer treatment, including solid tumors that are not responding to standard treatments, solid tumor in stage IIII, and multiple myeloma.